SI Bone is projected to record more than $200 million in worldwide revenue during fiscal year 2025, according to preliminary ...

Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20%SANTA CLARA, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in ...

Jim Cramer’s repeated description of SI-BONE (SIBN) as a “great, great speculation,” combined with fresh buy-side analyst ...

Maheshwari announced, "We're updating our full year revenue guidance to range between $198 million to $200 million. This implies year-over-year growth of approximately 18% to 20% as compared to the ...

SI-BONE reports strong revenue growth and improved financial metrics for Q4 2024 and FY 2024, achieving positive adjusted EBITDA. SI-BONE, Inc. reported strong financial results for the fourth quarter ...

SI-Bone shares rose in after-hours trading as three executives sold stock last week to cover RSU tax obligations.

SI-BONE, Inc. (NASDAQ:SIBN) is one of the stocks Jim Cramer shared his takes on. A caller asked about the company during the ...

SI-BONE, Inc., a company focused on medical technologies for sacropelvic disorders, announced it will release its financial results for the fourth quarter and full year of 2024 on February 24, 2025, ...

SANTA CLARA, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the fourth ...

Canaccord Genuity analyst Caitlin Cronin maintained a Buy rating on SI-Bone today and set a price target of $27.00. According to TipRanks, Cronin is a 4-star analyst with an average return of 15.7% ...

SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone ...